Journal: Pharmaceuticals

Article Title: Anti-COVID Drugs (MMV COVID Box) as Leishmanicidal Agents: Unveiling New Therapeutic Horizons

doi: 10.3390/ph17030266

Figure Lengend Snippet: Leishmanicidal activity against the promastigote stage of the selected compounds from MMV COVID Box. Values correspond to inhibitory concentrations 50 ± standard deviation (μM). w/a: without activity.

Article Snippet: After an initial screening, five pure compounds were purchased: Terconazole was obtained from Cymit Química S.L. (Pamplona, Spain); ABT-239 was purchased from MedChemExpress (Monmouth Junction, NJ, USA); and Bortezomib, Almitrine mesylate, and Midostaurin hydrate were purchased from Sigma-Aldrich (now Merck) (Darmstadt, Germany).

Techniques: Activity Assay, Standard Deviation

Journal: Pharmaceuticals

Article Title: Anti-COVID Drugs (MMV COVID Box) as Leishmanicidal Agents: Unveiling New Therapeutic Horizons

doi: 10.3390/ph17030266

Figure Lengend Snippet: 2D Chemical structures of the selected active compounds.

Article Snippet: After an initial screening, five pure compounds were purchased: Terconazole was obtained from Cymit Química S.L. (Pamplona, Spain); ABT-239 was purchased from MedChemExpress (Monmouth Junction, NJ, USA); and Bortezomib, Almitrine mesylate, and Midostaurin hydrate were purchased from Sigma-Aldrich (now Merck) (Darmstadt, Germany).

Techniques:

Journal: Pharmaceuticals

Article Title: Anti-COVID Drugs (MMV COVID Box) as Leishmanicidal Agents: Unveiling New Therapeutic Horizons

doi: 10.3390/ph17030266

Figure Lengend Snippet: Leishmanicidal activity against the amastigote stage of the selected compounds from MMV COVID Box and cytotoxic activity against murine macrophages (μM). Selectivity index (CC 50 /IC 50 ). w/a: without activity; n/d: not determined.

Article Snippet: After an initial screening, five pure compounds were purchased: Terconazole was obtained from Cymit Química S.L. (Pamplona, Spain); ABT-239 was purchased from MedChemExpress (Monmouth Junction, NJ, USA); and Bortezomib, Almitrine mesylate, and Midostaurin hydrate were purchased from Sigma-Aldrich (now Merck) (Darmstadt, Germany).

Techniques: Activity Assay

Journal: Pharmaceuticals

Article Title: Anti-COVID Drugs (MMV COVID Box) as Leishmanicidal Agents: Unveiling New Therapeutic Horizons

doi: 10.3390/ph17030266

Figure Lengend Snippet: Transmitted light, SytoxGreen (green), Hoechst (blue), and Propidium iodide (red) staining. Results after 24 h of incubation of L. amazonensis promastigotes with the IC90 of compounds. Negative control ( A – D ). Bortezomib ( E – H ); almitrine ( I – L ); terconazole ( M – P ); and ABT239 ( Q – T ). Images were captured using an EVOS FL Cell Imaging system (Thermo Fisher Scientific) (40×). Scale: 75 µm.

Article Snippet: After an initial screening, five pure compounds were purchased: Terconazole was obtained from Cymit Química S.L. (Pamplona, Spain); ABT-239 was purchased from MedChemExpress (Monmouth Junction, NJ, USA); and Bortezomib, Almitrine mesylate, and Midostaurin hydrate were purchased from Sigma-Aldrich (now Merck) (Darmstadt, Germany).

Techniques: Staining, Incubation, Negative Control, Imaging

Journal: Pharmaceuticals

Article Title: Anti-COVID Drugs (MMV COVID Box) as Leishmanicidal Agents: Unveiling New Therapeutic Horizons

doi: 10.3390/ph17030266

Figure Lengend Snippet: CellROX Deep Red staining. Results after 24 h of incubation of L. amazonensis promastigotes with the IC 90 of the compounds. Negative control ( A , B ); Positive control treated with H 2 O 2 ( E , F ); Bortezomib ( C , D ); almitrine ( G , H ); terconazole ( I , J ); and ABT-239 ( K , L ). Images were captured using an EVOS FL Cell Imaging system (Thermo Fisher Scientific) (100×). Scale: 20µm.

Article Snippet: After an initial screening, five pure compounds were purchased: Terconazole was obtained from Cymit Química S.L. (Pamplona, Spain); ABT-239 was purchased from MedChemExpress (Monmouth Junction, NJ, USA); and Bortezomib, Almitrine mesylate, and Midostaurin hydrate were purchased from Sigma-Aldrich (now Merck) (Darmstadt, Germany).

Techniques: Staining, Incubation, Negative Control, Positive Control, Imaging

Journal: Advanced Pharmaceutical Bulletin

Article Title: Self-nanoemulsifying System Optimization for Higher Terconazole Solubilization and Non-Irritant Ocular Administration

doi: 10.34172/apb.2020.047

Figure Lengend Snippet: Composition of different self nanoemulsifying systems with different oils:surfactant:co-surfactant ratios and their measured dependent responses

Article Snippet: Terconazole was supplied as a gift from Marcyrl Pharmaceutical Industries (Cairo, Egypt).

Techniques:

Journal: Drug Delivery

Article Title: PLGA-modified Syloid ® -based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations

doi: 10.1080/10717544.2022.2092239

Figure Lengend Snippet: Composition and characterization of terconazole-loaded Syloid ® microparticles during preliminary studies.

Article Snippet: Terconazole was provided by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques:

Journal: Drug Delivery

Article Title: PLGA-modified Syloid ® -based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations

doi: 10.1080/10717544.2022.2092239

Figure Lengend Snippet: Compositions and characterization of terconazole PLGA-modified Syloid ® microparticles.

Article Snippet: Terconazole was provided by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques: Concentration Assay

Journal: Drug Delivery

Article Title: PLGA-modified Syloid ® -based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations

doi: 10.1080/10717544.2022.2092239

Figure Lengend Snippet: Release profiles of terconazole-loaded Syloid ® microparticles during the preliminary studies compared to the drug suspension.

Article Snippet: Terconazole was provided by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques: Suspension

Journal: Drug Delivery

Article Title: PLGA-modified Syloid ® -based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations

doi: 10.1080/10717544.2022.2092239

Figure Lengend Snippet: (a) DSC curves and (b) X–ray diffractions for terconazole, PLGA, Syloid ® , SPA 50 -1 physical mixture without PLGA, SPA 50 -1 physical mixture with PLGA, the selected formulation SPA 50 -1 PLGA-free analogue and the selected formulation SPA 50 -1. Ph.mix: Physical mixture.

Article Snippet: Terconazole was provided by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques: Formulation

Journal: Drug Delivery

Article Title: PLGA-modified Syloid ® -based microparticles for the ocular delivery of terconazole: in-vitro and in-vivo investigations

doi: 10.1080/10717544.2022.2092239

Figure Lengend Snippet: SEM images of (a) Terconazole, (b & c) Syloid ® , (d) SPA 50 -1 PLGA-free analogue and (e & f) SPA 50 -1.

Article Snippet: Terconazole was provided by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques:

Journal: Pharmaceutics

Article Title: Cyclodextrin Stabilized Freeze-Dried Silica/Chitosan Nanoparticles for Improved Terconazole Ocular Bioavailability

doi: 10.3390/pharmaceutics14030470

Figure Lengend Snippet: Experimental runs and responses obtained for the factorial design of the freeze-dried terconazole-loaded silica/chitosan nanoparticles.

Article Snippet: Terconazole (TZ) was gifted by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques:

Journal: Pharmaceutics

Article Title: Cyclodextrin Stabilized Freeze-Dried Silica/Chitosan Nanoparticles for Improved Terconazole Ocular Bioavailability

doi: 10.3390/pharmaceutics14030470

Figure Lengend Snippet: Release profiles of terconazole from SCM8 and SCM8–1 formulations, compared to the drug suspension.

Article Snippet: Terconazole (TZ) was gifted by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques: Suspension

Journal: Pharmaceutics

Article Title: Cyclodextrin Stabilized Freeze-Dried Silica/Chitosan Nanoparticles for Improved Terconazole Ocular Bioavailability

doi: 10.3390/pharmaceutics14030470

Figure Lengend Snippet: ( a ) DSC curves and ( b ) X–ray diffractions for terconazole, chitosan HCl, MβCD and the selected formulation SCM8–1.

Article Snippet: Terconazole (TZ) was gifted by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques: Formulation

Journal: Pharmaceutics

Article Title: Cyclodextrin Stabilized Freeze-Dried Silica/Chitosan Nanoparticles for Improved Terconazole Ocular Bioavailability

doi: 10.3390/pharmaceutics14030470

Figure Lengend Snippet: Pharmacokinetic parameters of terconazole following the ocular administration of drug suspension and the selected formulation. SCM8-1 to the rabbits’ eyes.

Article Snippet: Terconazole (TZ) was gifted by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques: Suspension, Formulation

Journal: Pharmaceutics

Article Title: Cyclodextrin Stabilized Freeze-Dried Silica/Chitosan Nanoparticles for Improved Terconazole Ocular Bioavailability

doi: 10.3390/pharmaceutics14030470

Figure Lengend Snippet: Mean terconazole tear concentrations following the ocular administration of SCM8-1 formulation compared to drug suspension.

Article Snippet: Terconazole (TZ) was gifted by Minapharm Pharmaceuticals (Cairo, Egypt).

Techniques: Formulation, Suspension